Arbutus announces multiple abstracts accepted for presentation at aasld - the liver meeting® 2023

Imdusiran data will be highlighted in late breaking presentation warminster, pa., oct. 11, 2023 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that clinical data from the company's lead hbv focused asset, imdusiran (ab-729), an rnai therapeutic, and preclinical data from its oral pd-l1 inhibitor program, will be highlighted in oral and poster presentations, including a late breaking poster presentation at the american association for the study of liver diseases (aasld) – the liver meeting ® 2023, taking place from november 10-14, 2023 in boston, ma.
ABUS Ratings Summary
ABUS Quant Ranking